Injectafer (Ferric Carboxymaltose) Patent Expiration, LOE Window & CMS Spending
Injectafer (Ferric Carboxymaltose) by Daiichi Sankyo: FDA Orange Book core substance LOE 2027-02-05 (last listed 2028-02-15), 0 AB generics, $41.2M 2024 CMS Part D & Medicaid spend, and 8 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Daiichi Sankyo |
| FDA Application & Pathway | N203565 (NDA) |
| Exclusivity / Cliff Horizon | Near-Term Cliff (2028-2030) |
| Core Active-Ingredient LOE Date | 2027-02-05 |
| Last Listed Patent or Exclusivity Date | 2028-02-15 |
| Orange Book Patents (*PED Extensions) | 6 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $41.2M |
| 2024 Medicare Part D Spend | $0 |
| 2024 Medicaid Spend | $41.2M |
| Reported Wholesale Price Change (CA SB 17) | 8 WAC filings (max 26.5% 2-yr change) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Daiichi Sankyo across sibling Meru public-data platforms.